


Claims

1. A pyrimidinyl compound  
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-  
5 benzonitrile, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically  
isomeric form thereof.
2. A pyrimidinyl compound according to claim 1 wherein the pyrimidinyl compound is  
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-  
10 benzonitrile.
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and  
a therapeutically active amount of a pyrimidinyl compound according to claims 1 or 2.
- 15 4. A combination comprising a pyrimidinyl compound according to claims 1 or 2, and  
an antiretroviral compound, wherein said antiretroviral compound comprises at least  
one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse  
transcriptase inhibitor, a TIBO compound, an  $\alpha$ -APA compound, a TAT-inhibitor, a  
protease inhibitor, an immunomodulating agent, and mixtures thereof.  
20
5. A combination according to claim 4, wherein said nucleoside reverse transcriptase  
inhibitor comprises at least one of zidovudine (3'-azido-3'-deoxythymidine, AZT),  
didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine  
(3'-thia-2'-3'-dideoxycytidine, 3TC), and mixtures thereof.  
25
6. A combination according to claim 4, wherein said non-nucleoside reverse  
transcriptase inhibitors comprises at least one of suramine, pentamidine, thymopentin,  
castanospermine, efavirenz, dextran (dextran sulfate), foscarnet-sodium (trisodium  
phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6*H*-dipyrido-[3,2-*b* : 2',3'-*e*][1,4]diazepin-6-one), tacrine (tetrahydroaminoacridine), and mixtures  
thereof.  
30
7. A combination according to claim 4, wherein said TIBO compound comprises  
(S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1*H*)-thione.  
35

8. A combination according to claim 4, wherein said  $\alpha$ -APA compound comprises  $\alpha$ -[(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide.
9. A combination according to claim 4, wherein said protease inhibitor comprises at least one of indinavir, ritonavir, saquinavir, ABT-378, and mixtures thereof.
10. A combination according to claim 4, comprising at least one of RO-5-3335, levamisole, and mixtures thereof.
- 10 11. A combination according to claim 5, further comprising a pharmaceutically acceptable carrier.
12. A combination according to claim 6, further comprising a pharmaceutically acceptable carrier.
- 15 13. A combination according to claim 7, further comprising a pharmaceutically acceptable carrier.
14. A combination according to claim 8, further comprising a pharmaceutically acceptable carrier.
- 20 15. A combination according to claim 9, further comprising a pharmaceutically acceptable carrier.
- 25 16. A combination according to claim 10, further comprising a pharmaceutically acceptable carrier.
17. A combination according to claim 4 wherein said pyrimidinyl compound and said antiretroviral compound are combined in a single preparation.
- 30 18. A combination according to claim 17, further comprising a pharmaceutically acceptable carrier.
19. A process for preparing a compound as claimed in claim 2, comprising reacting a compound of formula



with NH<sub>3</sub> in the presence of a reaction inert solvent.

20. A process according to claim 19, wherein said reacting is performed in the  
5 presence of a base.

21. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a compound according to claims 1 or 2.

10 22. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a combination according to claim 4.

15